Pathogenic and therapeutic role of miRNAs in breast cancer

Frontiers in Bioscience - Landmark

Volumn 19, Issue 1, 2014, Pages 1-11

  Kurisetty, Vittal Venkatasatya ^a   Lakshmanaswamy, Rajkumar ^a   Damodaran, Chendil ^a  

^a Texas Tech University Health Sciences Center El Paso   (United States)

Author keywords

Biomarker; Breast cancer; MicroRNA; Review; Therapeutic marker

Indexed keywords

MICRORNA;

BLOOD; BREAST TUMOR; FEMALE; GENETICS; HUMAN; PHYSIOLOGY; REVIEW;

BREAST NEOPLASMS; FEMALE; HUMANS; MICRORNAS;

EID: 84904285389     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4192     Document Type: Review

References (120)

1. D. V. Dugas and B. Bartel: MicroRNA regulation of gene expression in plants. Curr Opin Plant Biol, 7(5), 512-20 (2004)
2. I. Bentwich: A postulated role for microRNA in cellular differentiation. FASEB J, 19(8), 875-9 (2005)
3. B. P. Lewis, C. B. Burge and D. P. Bartel: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 120(1), 15-20 (2005)
4. J. M. Friedman, P. A. Jones and G. Liang: The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb group protein EZH2 in cancer. Cell Cycle, 8(15), 2313-4 (2009)
5. J. M. Friedman, G. Liang, C. C. Liu, E. M. Wolff, Y. C. Tsai, W. Ye, X. Zhou and P. A. Jones: The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res, 69(6), 2623-9 (2009)
6. L. P. Lim, M. E. Glasner, S. Yekta, C. B. Burge and D. P. Bartel: Vertebrate microRNA genes. Science, 299(5612), 1540 (2003)
7. Q. Jiang, Y. Wang, Y. Hao, L. Juan, M. Teng, X. Zhang, M. Li, G. Wang and Y. Liu: miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res, 37(Database issue), D98-104 (2009)
8. A. Mencia, S. Modamio-Hoybjor, N. Redshaw, M. Morin, F. Mayo-Merino, L. Olavarrieta, L. A. Aguirre, I. del Castillo, K. P. Steel, T. Dalmay, F. Moreno and M. A. Moreno-Pelayo: Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss. Nat Genet, 41(5), 609-13 (2009)
9. A. E. Hughes, D. T. Bradley, M. Campbell, J. Lechner, D. P. Dash, D. A. Simpson and C. E. Willoughby: Mutation altering the miR-184 seed region causes familial keratoconus with cataract. Am J Hum Genet, 89(5), 628-33 (2011)
10. H. He, K. Jazdzewski, W. Li, S. Liyanarachchi, R. Nagy, S. Volinia, G. A. Calin, C. G. Liu, K. Franssila, S. Suster, R. T. Kloos, C. M. Croce and A. de la Chapelle: The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A, 102(52), 19075-80 (2005)
11. L. He, J. M. Thomson, M. T. Hemann, E. Hernando-Monge, D. Mu, S. Goodson, S. Powers, C. Cordon-Cardo, S. W. Lowe, G. J. Hannon and S. M. Hammond: A microRNA polycistron as a potential human oncogene. Nature, 435(7043), 828-33 (2005)
12. M. Mraz, K. Malinova, J. Mayer and S. Pospisilova: MicroRNA isolation and stability in stored RNA samples. Biochem Biophys Res Commun, 390(1), 1-4 (2009)
13. M. Mraz, S. Pospisilova, K. Malinova, I. Slapak and J. Mayer: MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes. Leuk Lymphoma, 50(3), 506-9 (2009)
14. M. Mraz, K. Malinova, J. Kotaskova, S. Pavlova, B. Tichy, J. Malcikova, K. Stano Kozubik, J. Smardova, Y. Brychtova, M. Doubek, M. Trbusek, J. Mayer and S. Pospisilova: miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia, 23(6), 1159-63 (2009)
15. K. A. O'Donnell, E. A. Wentzel, K. I. Zeller, C. V. Dang and J. T. Mendell: c-Myc-regulated microRNAs modulate E2F1 expression. Nature, 435(7043), 839-43 (2005)
16. S. Costinean, N. Zanesi, Y. Pekarsky, E. Tili, S. Volinia, N. Heerema and C. M. Croce: Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A, 103(18), 7024-9 (2006)
17. N. C. Lau, L. P. Lim, E. G. Weinstein and D. P. Bartel: An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science, 294(5543), 858-62 (2001)
18. Y. Lee, M. Kim, J. Han, K. H. Yeom, S. Lee, S. H. Baek and V. N. Kim: MicroRNA genes are transcribed by RNA polymerase II. EMBO J, 23(20), 4051-60 (2004)
19. Y. S. Lee, K. Nakahara, J. W. Pham, K. Kim, Z. He, E. J. Sontheimer and R. W. Carthew: Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways. Cell, 117(1), 69-81 (2004)
20. R. Lee, R. Feinbaum and V. Ambros: A short history of a short RNA. Cell, 116(2 Suppl), S89-92, 1 p following S96 (2004)
21. X. Cai, C. H. Hagedorn and B. R. Cullen: Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA, 10(12), 1957-66 (2004)
22. M. J. Weber: New human and mouse microRNA genes found by homology search. FEBS J, 272(1), 59-73 (2005)
23. V. N. Kim: MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol, 6(5), 376-85 (2005)
24. V. N. Kim: Small RNAs: classification, biogenesis, and function. Mol Cells, 19(1), 1-15 (2005)
25. S. Baskerville and D. P. Bartel: Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA, 11(3), 241-7 (2005)
26. J. R. Harris, P. K. Brown, S. Coughlin, M. E. Fernandez, J. R. Hebert, J. Kerner, M. Prout, R. Schwartz, E. J. Simoes, C. White and K. Wilson: The cancer prevention and control research network. Prev Chronic Dis, 2(1), A21 (2005)
27. H. Schirrmeister, A. Guhlmann, J. Kotzerke, C. Santjohanser, T. Kuhn, R. Kreienberg, P. Messer, K. Nussle, K. Elsner, G. Glatting, H. Trager, B. Neumaier, C. Diederichs and S. N. Reske: Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol, 17(8), 2381-9 (1999)
28. G. Schwartsmann: Breast cancer in South America: challenges to improve early detection and medical management of a public health problem. J Clin Oncol, 19(18 Suppl), 118S-124S (2001)
29. R. J. Cote, H. F. Peterson, B. Chaiwun, R. D. Gelber, A. Goldhirsch, M. Castiglione-Gertsch, B. Gusterson and A. M. Neville: Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet, 354(9182), 896-900 (1999)
30. F. Podo, F. Sardanelli, R. Canese, G. D'Agnolo, P. G. Natali, M. Crecco, M. L. Grandinetti, R. Musumeci, G. Trecate, S. Bergonzi, T. De Simone, C. Costa, B. Pasini, S. Manuokian, G. B. Spatti, D. Vergnaghi, S. Morassut, M. Boiocchi, R. Dolcetti, A. Viel, C. De Giacomi, A. Veronesi, F. Coran, V. Silingardi, D. Turchett, L. Cortesi, M. De Santis, M. Federico, R. Romagnoli, S. Ferrari, G. Bevilacqua, C. Bartolozzi, M. A. Caligo, A. Cilotti, C. Marini, S. Cirillo, V. Marra, L. Martincich, A. Contegiacomo, M. Pensabene, I. Capuano, G. B. Burgazzi, A. Petrillo, L. Bonomo, A. Carriero, R. Mariani-Costantini, P. Battista, A. Cama, G. Palca, C. Di Maggio, E. D'Andrea, M. Bazzocchi, G. E. Francescutti, C. Zuiani, V. Londero, I. Zunnui, C. Gustavino, M. G. Centurioni, A. Iozzelli, P. Panizza and A. Del Maschio: The Italian multicentre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res, 21(3 Suppl), 115-24 (2002)
31. R. M. Clark: An approach to the detection and management of early breast cancer. Can Med Assoc J, 108(5), 599-602 passim (1973)
32. E. van Rooij and E. N. Olson: microRNAs put their signatures on the heart. Physiol Genomics, 31(3), 365-6 (2007)
33. E. van Rooij and E. N. Olson: MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest, 117(9), 2369-76 (2007)
34. E. van Rooij, L. B. Sutherland, X. Qi, J. A. Richardson, J. Hill and E. N. Olson: Control of stress-dependent cardiac growth and gene expression by a microRNA. Science, 316(5824), 575-9 (2007)
35. H. M. Heneghan, N. Miller and M. J. Kerin: Role of microRNAs in obesity and the metabolic syndrome. Obes Rev, 11(5), 354-61 (2010)
36. B. J. Small, K. S. Rawson, E. Walsh, H. S. Jim, T. F. Hughes, L. Iser, M. A. Andrykowski and P. B. Jacobsen: Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer (2010)
37. B. Zhang, X. Pan, G. P. Cobb and T. A. Anderson: microRNAs as oncogenes and tumor suppressors. Dev Biol, 302(1), 1-12 (2007)
38. J. M. Cummins and V. E. Velculescu: Implications of micro-RNA profiling for cancer diagnosis. Oncogene, 25(46), 6220-7 (2006)
39. J. M. Cummins, Y. He, R. J. Leary, R. Pagliarini, L. A. Diaz, Jr., T. Sjoblom, O. Barad, Z. Bentwich, A. E. Szafranska, E. Labourier, C. K. Raymond, B. S. Roberts, H. Juhl, K. W. Kinzler, B. Vogelstein and V. E. Velculescu: The colorectal microRNAome. Proc Natl Acad Sci U S A, 103(10), 3687-92 (2006)
40. H. M. Heneghan, N. Miller and M. J. Kerin: Circulating miRNA signatures: promising prognostic tools for cancer. J Clin Oncol, 28(29), e573-4; author reply e575-6 (2010)
41. H. M. Heneghan, N. Miller and M. J. Kerin: MiRNAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol, 10(5), 543-50 (2010)
42. H. M. Heneghan, N. Miller, A. J. Lowery, K. J. Sweeney, J. Newell and M. J. Kerin: Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg, 251(3), 499-505 (2010)
43. M. S. Weinberg and M. J. Wood: Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics. Hum Mol Genet, 18(R1), R27-39 (2009)
44. M. Gotte: MicroRNAs in breast cancer pathogenesis. Minerva Ginecol, 62(6), 559-71 (2010)
45. S. B. Greene, J. I. Herschkowitz and J. M. Rosen: Small players with big roles: microRNAs as targets to inhibit breast cancer progression. Curr Drug Targets, 11(9), 1059-73 (2010)
46. B. Qian, D. Katsaros, L. Lu, M. Preti, A. Durando, R. Arisio, L. Mu and H. Yu: High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat, 117(1), 131-40 (2009)
47. L. X. Yan, X. F. Huang, Q. Shao, M. Y. Huang, L. Deng, Q. L. Wu, Y. X. Zeng and J. Y. Shao: MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA, 14(11), 2348-60 (2008)
48. S. Ali, A. Ahmad, S. Banerjee, S. Padhye, K. Dominiak, J. M. Schaffert, Z. Wang, P. A. Philip and F. H. Sarkar: Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res, 70(9), 3606-17 (2010)
49. S. Zhu, M. L. Si, H. Wu and Y. Y. Mo: MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem, 282(19), 14328-36 (2007)
50. L. Smith, K. J. Welham, M. B. Watson, P. J. Drew, M. J. Lind and L. Cawkwell: The proteomic analysis of cisplatin resistance in breast cancer cells. Oncol Res, 16(11), 497-506 (2007)
51. R. Nieves-Alicea, N. H. Colburn, A. M. Simeone and A. M. Tari: Programmed cell death 4 inhibits breast cancer cell invasion by increasing tissue inhibitor of metalloproteinases-2 expression. Breast Cancer Res Treat, 114(2), 203-9 (2009
52. L. Qi, J. Bart, L. P. Tan, I. Platteel, T. Sluis, S. Huitema, G. Harms, L. Fu, H. Hollema and A. Berg: Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer, 9, 163 (2009)
53. T. H. Huang, F. Wu, G. B. Loeb, R. Hsu, A. Heidersbach, A. Brincat, D. Horiuchi, R. J. Lebbink, Y. Y. Mo, A. Goga and M. T. McManus: Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. J Biol Chem, 284(27), 18515-24 (2009)
54. J. Du, S. Yang, D. An, F. Hu, W. Yuan, C. Zhai and T. Zhu: BMP-6 inhibits microRNA-21 expression in breast cancer through repressing deltaEF1 and AP-1. Cell Res, 19(4), 487-96 (2009)
55. Z. Lu, M. Liu, V. Stribinskis, C. M. Klinge, K. S. Ramos, N. H. Colburn and Y. Li: MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene, 27(31), 4373-9 (2008)
56. D. Ota, K. Mimori, T. Yokobori, M. Iwatsuki, A. Kataoka, N. Masuda, H. Ishii, S. Ohno and M. Mori: Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients. Int J Oncol, 38(4), 955-62 (2011)
57. T. Schmid, M. M. Bajer, J. S. Blees, L. K. Eifler, L. Milke, D. Rubsamen, K. Schulz, A. Weigert, A. R. Baker, N. H. Colburn and B. Brune: Inflammation-induced loss of Pdcd4 is mediated by phosphorylation-dependent degradation. Carcinogenesis, 32(10), 1427-33 (2011)
58. B. A. Walter, G. Gomez-Macias, V. A. Valera, M. Sobel and M. J. Merino: miR-21 Expression in Pregnancy-Associated Breast Cancer: A Possible Marker of Poor Prognosis. J Cancer, 2, 67-75 (2011)
59. D. Wang, J. Huang and Z. Hu: RNA helicase DDX5 regulates microRNA expression and contributes to cytoskeletal reorganization in basal breast cancer cells. Mol Cell Proteomics, 11(2), M111 011932 (2012)
60. Y. H. Wen, X. Shi, L. Chiriboga, S. Matsahashi, H. Yee and O. Afonja: Alterations in the expression of PDCD4 in ductal carcinoma of the breast. Oncol Rep, 18(6), 1387-93 (2007)
61. N. S. Wickramasinghe, T. T. Manavalan, S. M. Dougherty, K. A. Riggs, Y. Li and C. M. Klinge: Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res, 37(8), 2584-95 (2009)
62. S. Zhu, H. Wu, F. Wu, D. Nie, S. Sheng and Y. Y. Mo: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res, 18(3), 350-9 (2008)
63. L. X. Yan, Q. N. Wu, Y. Zhang, Y. Y. Li, D. Z. Liao, J. H. Hou, J. Fu, M. S. Zeng, J. P. Yun, Q. L. Wu, Y. X. Zeng and J. Y. Shao: Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res, 13(1), R2 (2011)
64. M. L. Si, S. Zhu, H. Wu, Z. Lu, F. Wu and Y. Y. Mo: miR-21-mediated tumor growth. Oncogene, 26(19), 2799-803 (2007)
65. M. Zhou, Z. Liu, Y. Zhao, Y. Ding, H. Liu, Y. Xi, W. Xiong, G. Li, J. Lu, O. Fodstad, A. I. Riker and M. Tan: MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem, 285(28), 21496-507 (2010)
66. M. T. Le, N. Shyh-Chang, S. L. Khaw, L. Chin, C. Teh, J. Tay, E. O'Day, V. Korzh, H. Yang, A. Lal, J. Lieberman, H. F. Lodish and B. Lim: Conserved regulation of p53 network dosage by microRNA-125b occurs through evolving miRNA-target gene pairs. PLoS Genet, 7(9), e1002242 (2011)
67. K. Hart, N. E. Landvik, H. Lind, V. Skaug, A. Haugen and S. Zienolddiny: A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer. Lung Cancer, 71(2), 123-9 (2011)
68. A. Juwle and D. Saranath: BRCA1/BRCA2 gene mutations/SNPs and BRCA1 haplotypes in early-onset breast cancer patients of Indian ethnicity. Med Oncol (2012)
69. N. Eriksson, G. M. Benton, C. B. Do, A. K. Kiefer, J. L. Mountain, D. A. Hinds, U. Francke and J. Y. Tung: Genetic variants associated with breast size also influence breast cancer risk. BMC Med Genet, 13(1), 53 (2012)
70. P. Saetrom, J. Biesinger, S. M. Li, D. Smith, L. F. Thomas, K. Majzoub, G. E. Rivas, J. Alluin, J. J. Rossi, T. G. Krontiris, J. Weitzel, M. B. Daly, A. B. Benson, J. M. Kirkwood, P. J. O'Dwyer, R. Sutphen, J. A. Stewart, D. Johnson and G. P. Larson: A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res, 69(18), 7459-65 (2009)
71. G. K. Scott, A. Goga, D. Bhaumik, C. E. Berger, C. S. Sullivan and C. C. Benz: Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem, 282(2), 1479-86 (2007)
72. M. V. Iorio, M. Ferracin, C. G. Liu, A. Veronese, R. Spizzo, S. Sabbioni, E. Magri, M. Pedriali, M. Fabbri, M. Campiglio, S. Menard, J. P. Palazzo, A. Rosenberg, P. Musiani, S. Volinia, I. Nenci, G. A. Calin, P. Querzoli, M. Negrini and C. M. Croce: MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65(16), 7065-70 (2005)
73. B. D. Adams, H. Furneaux and B. A. White: The microribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol, 21(5), 1132-47 (2007)
74. G. Di Leva, P. Gasparini, C. Piovan, A. Ngankeu, M. Garofalo, C. Taccioli, M. V. Iorio, M. Li, S. Volinia, H. Alder, T. Nakamura, G. Nuovo, Y. Liu, K. P. Nephew and C. M. Croce: MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst, 102(10), 706-21 (2010)
75. G. Song, Y. Zhang and L. Wang: MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem, 284(46), 31921-7 (2009)
76. T. E. Miller, K. Ghoshal, B. Ramaswamy, S. Roy, J. Datta, C. L. Shapiro, S. Jacob and S. Majumder: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem, 283(44), 29897-903 (2008)
77. V. Ambros: microRNAs: tiny regulators with great potential. Cell, 107(7), 823-6 (2001)
78. R. C. Lee and V. Ambros: An extensive class of small RNAs in Caenorhabditis elegans. Science, 294(5543), 862-4 (2001)
79. F. Yu, H. Yao, P. Zhu, X. Zhang, Q. Pan, C. Gong, Y. Huang, X. Hu, F. Su, J. Lieberman and E. Song: let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell, 131(6), 1109-23 (2007)
80. A. J. Lowery, N. Miller, R. E. McNeill and M. J. Kerin: MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res, 14(2), 360-5 (2008)
81. L. Ma and R. A. Weinberg: MicroRNAs in malignant progression. Cell Cycle, 7(5), 570-2 (2008)
82. L. Ma, J. Teruya-Feldstein and R. A. Weinberg: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 449(7163), 682-8 (2007)
83. L. Ma, J. Young, H. Prabhala, E. Pan, P. Mestdagh, D. Muth, J. Teruya-Feldstein, F. Reinhardt, T. T. Onder, S. Valastyan, F. Westermann, F. Speleman, J. Vandesompele and R. A. Weinberg: miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol, 12(3), 247-56 (2010)
84. U. Lehmann, B. Hasemeier, M. Christgen, M. Muller, D. Romermann, F. Langer and H. Kreipe: Epigenetic inactivation of microRNA gene hsa-mir-9-1 in human breast cancer. J Pathol, 214(1), 17-24 (2008)
85. M. Feng, Z. Li, M. Aau, C. H. Wong, X. Yang and Q. Yu: Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation. Oncogene, 30(19), 2242-51 (2011)
86. L. J. Eichner, M. C. Perry, C. R. Dufour, N. Bertos, M. Park, J. St-Pierre and V. Giguere: miR-378(&z.ast;) mediates metabolic shift in breast cancer cells via the PGC-1beta/ERRgamma transcriptional pathway. Cell Metab, 12(4), 352-61 (2010)
87. C. Roth, B. Rack, V. Muller, W. Janni, K. Pantel and H. Schwarzenbach: Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res, 12(6), R90 (2010)
88. P. S. Mitchell, R. K. Parkin, E. M. Kroh, B. R. Fritz, S. K. Wyman, E. L. Pogosova-Agadjanyan, A. Peterson, J. Noteboom, K. C. O'Briant, A. Allen, D. W. Lin, N. Urban, C. W. Drescher, B. S. Knudsen, D. L. Stirewalt, R. Gentleman, R. L. Vessella, P. S. Nelson, D. B. Martin and M. Tewari: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A, 105(30), 10513-8 (2008)
89. C. C. Pritchard, E. Kroh, B. Wood, J. D. Arroyo, K. J. Dougherty, M. M. Miyaji, J. F. Tait and M. Tewari: Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) (2011)
90. J. D. Arroyo, J. R. Chevillet, E. M. Kroh, I. K. Ruf, C. C. Pritchard, D. F. Gibson, P. S. Mitchell, C. F. Bennett, E. L. Pogosova-Agadjanyan, D. L. Stirewalt, J. F. Tait and M. Tewari: Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A, 108(12), 5003-8 (2011)
91. R. A. McDonald, A. Hata, M. R. Maclean, N. W. Morrell and A. H. Baker: MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodelling. Cardiovasc Res (2011)
92. J. S. McDonald, D. Milosevic, H. V. Reddi, S. K. Grebe and A. Algeciras-Schimnich: Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem, 57(6), 833-40 (2011)
93. M. A. Cortez, C. Bueso-Ramos, J. Ferdin, G. Lopez-Berestein, A. K. Sood and G. A. Calin: MicroRNAs in body fluids - the mix of hormones and biomarkers. Nat Rev Clin Oncol, 8(8), 467-77 (2011)
94. S. K. Gupta, C. Bang and T. Thum: Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet, 3(5), 484-8 (2010)
95. S. Gilad, E. Meiri, Y. Yogev, S. Benjamin, D. Lebanony, N. Yerushalmi, H. Benjamin, M. Kushnir, H. Cholakh, N. Melamed, Z. Bentwich, M. Hod, Y. Goren and A. Chajut: Serum microRNAs are promising novel biomarkers. PLoS One, 3(9), e3148 (2008)
96. M. G. Schrauder, R. Strick, R. Schulz-Wendtland, P. L. Strissel, L. Kahmann, C. R. Loehberg, M. P. Lux, S. M. Jud, A. Hartmann, A. Hein, C. M. Bayer, M. R. Bani, S. Richter, B. R. Adamietz, E. Wenkel, C. Rauh, M. W. Beckmann and P. A. Fasching: Circulating Micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection. PLoS One, 7(1), e29770 (2012)
97. K. Zen and C. Y. Zhang: Circulating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev (2010)
98. J. C. Brase, D. Wuttig, R. Kuner and H. Sultmann: Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer, 9, 306 (2010)
99. Y. Tie, B. Liu, H. Fu and X. Zheng: Circulating miRNA and cancer diagnosis. Sci China C Life Sci, 52(12), 1117-22 (2009)
100. C. A. Andorfer, B. M. Necela, E. A. Thompson and E. A. Perez: MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol Med, 17(6), 313-9 (2011)
101. E. S. Lianidou, D. Mavroudis, G. Sotiropoulou, S. Agelaki and K. Pantel: What's new on circulating tumor cells? A meeting report. Breast Cancer Res, 12(4), 307 (2010)
102. J. S. Ross and E. A. Slodkowska: Circulating and disseminated tumor cells in the management of breast cancer. Am J Clin Pathol, 132(2), 237-45 (2009)
103. M. Ignatiadis and M. Reinholz: Minimal residual disease and circulating tumor cells in breast cancer. Breast Cancer Res, 13(5), 222 (2011)
104. J. Kraan, S. Sleijfer, M. H. Strijbos, M. Ignatiadis, D. Peeters, J. Y. Pierga, F. Farace, S. Riethdorf, T. Fehm, L. Zorzino, A. G. Tibbe, M. Maestro, R. Gisbert-Criado, G. Denton, J. S. de Bono, C. Dive, J. A. Foekens and J. W. Gratama: External quality assurance of circulating tumor cell enumeration using the CellSearch((R)) system: a feasibility study. Cytometry B Clin Cytom, 80(2), 112-8 (2011)
105. M. Ignatiadis, F. Rothe, C. Chaboteaux, V. Durbecq, G. Rouas, C. Criscitiello, J. Metallo, N. Kheddoumi, S. K. Singhal, S. Michiels, I. Veys, J. Rossari, D. Larsimont, B. Carly, M. Pestrin, S. Bessi, F. Buxant, F. Liebens, M. Piccart and C. Sotiriou: HER2-positive circulating tumor cells in breast cancer. PLoS One, 6(1), e15624 (2011)
106. S. W. Fu, L. Chen and Y. G. Man: miRNA Biomarkers in Breast Cancer Detection and Management. J Cancer, 2, 116-22 (2011)
107. B. Mostert, A. M. Sieuwerts, J. W. Martens and S. Sleijfer: Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert Rev Mol Diagn, 11(3), 259-75 (2011)
108. L. F. Sempere: Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer. Expert Rev Mol Diagn, 11(8), 813-27 (2011)
109. M. Preis, T. B. Gardner, S. R. Gordon, J. M. Pipas, T. A. Mackenzie, E. E. Klein, D. S. Longnecker, E. J. Gutmann, L. F. Sempere and M. Korc: MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Clin Cancer Res, 17(17), 5812-21 (2011)
110. R. Zhao, J. Wu, W. Jia, C. Gong, F. Yu, Z. Ren, K. Chen, J. He and F. Su: Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie, 34(12), 675-80 (2011)
111. H. Wang, G. Tan, L. Dong, L. Cheng, K. Li, Z. Wang and H. Luo: Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One, 7(4), e34210 (2012)
112. Z. Hu, J. Dong, L. E. Wang, H. Ma, J. Liu, Y. Zhao, J. Tang, X. Chen, J. Dai, Q. Wei, C. Zhang and H. Shen: Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis, 33(4), 828-34 (2012)
113. M. Nugent, N. Miller and M. J. Kerin: Circulating miR-34a levels are reduced in colorectal cancer. J Surg Oncol (2012)
114. N. Healy, H. Heneghan, N. Miller, C. Osborne, R. Schiff and M. Kerin: Systemic miRNAs as potential biomarkers for malignancy. Int J Cancer (2012)
115. H. Zhao, J. Shen, L. Medico, D. Wang, C. B. Ambrosone and S. Liu: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS One, 5(10), e13735 (2010)
116. J. Krutzfeldt, N. Rajewsky, R. Braich, K. G. Rajeev, T. Tuschl, M. Manoharan and M. Stoffel: Silencing of microRNAs in vivo with 'antagomirs'. Nature, 438(7068), 685-9 (2005)
117. H. Zhou, J. M. Guo, Y. R. Lou, X. J. Zhang, F. D. Zhong, Z. Jiang, J. Cheng and B. X. Xiao: Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J Mol Med (Berl), 88(7), 709-17 (2010)
118. K. Pantel, R. H. Brakenhoff and B. Brandt: Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer, 8(5), 329-40 (2008)
119. M. Tsujiura, D. Ichikawa, S. Komatsu, A. Shiozaki, H. Takeshita, T. Kosuga, H. Konishi, R. Morimura, K. Deguchi, H. Fujiwara, K. Okamoto and E. Otsuji: Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer, 102(7), 1174-9 (2010)
120. Z. Huang, D. Huang, S. Ni, Z. Peng, W. Sheng and X. Du: Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 127(1), 118-26 (2010)